Infertility drugs are medications prescribed to treat infertility and enhance fertility in individuals. Some common infertility drugs include clomiphene citrate, letrozole, gonadotropins, and others. Clomiphene citrate and letrozole are the most prescribed medications for ovulation induction in polycystic ovary syndrome (PCOS) and ovulation disorders. Gonadotropins such as follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are often used during in vitro fertilization (IVF) to stimulate egg development. The global infertility drugs market witnessed high growth in the past decade due to rising numbers of couples consulting fertility specialists and increased adoption of assisted reproductive technologies (ART) such as IVF. Changing lifestyles, late pregnancies, higher prevalence of polycystic ovary syndrome and other medical conditions are fueling the demand for infertility treatment and drugs.

The global Infertility Drugs Market is estimated to be valued at Us$ 3699.8 Mn in 2023 and is expected to exhibit a CAGR Of 5.9% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:

The key driver mentioned in the heading, increasing adoption of assisted reproductive technologies, is a major factor augmenting market growth. Assisted reproductive technology (ART) procedures like in-vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) have gained significant popularity globally as they help increase pregnancy rates in couples suffering from infertility. The number of IVF cycles performed annually is growing steadily worldwide. In addition, advancements in infertility treatment technologies and introduction of innovative drugs is also boosting the market. Some new infertility treatment approaches gaining attention include cryopreservation of gametes and embryos, preimplantation genetic testing, fertility preservation (elective egg freezing), and intracytoplasmic sperm injection (ICSI). However, high cost of fertility treatment and lengthy process associated with IVF may restrain market growth to some extent over the forecast period.

Segment Analysis

The global infertility drugs market is segmented into male infertility drugs and female infertility drugs. The female infertility drugs segment dominates the market and accounts for around 60% share owing to higher prevalence of infertility issues among women compared to men. Factors such as rising number of delayed pregnancies, increasing stress levels that negatively impact fertility, and growing acceptance of contraceptives are boosting the growth of female infertility drugs segment.

PEST Analysis

Political: Governments in various countries are introducing favorable regulations and policies to increase availability of infertility treatment drugs. Several governments are also organizing awareness campaigns about infertility causes and treatment options.

Economic: Rising incomes and growing health awareness are driving people to opt for infertility treatment. The overall cost of infertility treatment has also reduced over time, making it more affordable.

Social: Social stigma associated with childlessness is reducing due to increasing social acceptance of modern lifestyles where people delay pregnancies. Growing single parenthood and same-sex marriages are also impacting the demand for infertility drugs.

Technological: Advancements in fertility treatments such as IVF, IUI, fertility medications, and cryopreservation are improving success rates of these procedures. Novel drug delivery systems and customized fertility treatment plans offer new growth opportunities.

Key Takeaways

The Global Infertility Drugs Market  Demand is expected to witness high growth in the coming years supported by rising infertility rates, growing healthcare expenditure on fertility treatment, new product launches, and increasing social acceptance of advanced fertility treatments. The global Infertility Drugs Market is estimated to be valued at US$ 3699.8 Mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030.

Regional analysis

North America presently holds the largest share in the global infertility drugs market owing to high awareness levels about modern fertility treatment options and significant healthcare spending in the area. Asia Pacific region is likely to be the fastest growing market driven by expanding medical tourism industry in countries like India and growing number of local participants entering the fertility space.

Key players

Key players operating in the infertility drugs market are Merck & Co., Ferring Pharmaceuticals, Novartis AG, Sanofi S.A., Eli Lilly and Company. Merck & Co. has a strong portfolio of fertility drugs and leads the market followed by Ferring Pharmaceuticals and Novartis AG. These companies focus on expanding their product offerings through strategic acquisitions and partnerships to consolidate their market position further.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it